Tuesday, May 09, 2017 3:55:03 PM
Many factors will impact whether or not one sees results from Niagen usage, but, if anyone experiences an allergic reaction they should stop taking it. A pharmacist or Dr could be consulted to see if there is any interaction with other meds, but, the more likely culprit would be the filler used. Switching to another brand may solve the issue. All sold in the US use the Chromadex ingredient, so, the only difference would be in fillers. Just make sure to buy product made in the US.
Dosage is another issue. Some have commented on my articles that they have seen benefit from 125mg, but, those are rare. It seems most take 500mg.
Another thing is to verify that you are actually taking nicotinimide riboside. It may seem odd, but, I've spoke to several now that have mistakenly taken Niacin instead of Niagen not realizing the difference. The mistake must have happened while price shopping online and simply grabbing the wrong product? It's difficult for me to understand, but, I've had more than one tell me about that mistake.
My experience has been and continues to be great. I'm not a biologist, md or dietician. I don't hold shares long or short. All I can give is personal usage experience. However, I did do an interview with Dr Brenner that you may find of interest.
https://seekingalpha.com/article/4040764-chromadex-response-claim-niagen-just-expensive-vitamin-b3
To follow KarinCA, click here then click "Follow This Member" under my photo.
Be kinder than necessary, for everyone you meet is fighting some kind of battle.
Recent CDXC News
- ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference • Business Wire • 09/26/2024 08:12:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 12:32:40 PM
- ChromaDex Appoints Ozan Pamir as Chief Financial Officer • Business Wire • 09/20/2024 12:32:00 PM
- ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics • Business Wire • 09/10/2024 12:32:00 PM
- ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions • Business Wire • 09/09/2024 12:34:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2024 11:06:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/23/2024 03:52:27 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024 • Business Wire • 08/23/2024 12:34:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 10:15:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 10:15:03 AM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/21/2024 10:06:58 AM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/21/2024 10:05:57 AM
- ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+ • Business Wire • 08/19/2024 12:32:00 PM
- ChromaDex Corporation Reports Second Quarter 2024 Financial Results • Business Wire • 08/07/2024 08:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:02:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:01:36 PM
- ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference • Business Wire • 08/05/2024 12:32:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 08:52:56 PM
- ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024 • Business Wire • 07/24/2024 12:34:00 PM
- ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs) • Business Wire • 07/23/2024 12:32:00 PM
- ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel • Business Wire • 07/22/2024 12:34:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 08:00:18 PM
- ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August • Business Wire • 07/16/2024 12:34:00 PM
- ChromaDex to Join Russell 2000® Index • Business Wire • 07/01/2024 12:32:00 PM
- Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD) • Business Wire • 06/24/2024 12:32:00 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM